What specific financial forecasts did Bristol Myers Squibb raise for 2026, and what were the previous ranges?

Bristol Myers Squibb raised its full-year 2026 revenue forecast to $49 billion to $50 billion, up from its prior range of $46 billion to $47.5 billion; it also increased its adjusted 2026 earnings per share forecast to $6.75 to $7.00, from a previous outlook of $6.05 to $6.35.

Which drugs drove Bristol Myers Squibb's stronger-than-expected Q2 2024 results, and how did their sales compare to analyst expectations?

Strong sales of Eliquis ($4.48 billion, +22% YoY, above $4.06 billion estimate), Reblozyl ($735 million vs. $664 million estimate), Camzyos ($416 million vs. $365 million estimate), and Breyanzi ($484 million vs. $422 million estimate) drove the results; Eliquis' U.S. new prescription share is approaching 80%, and the company raised its full-year Eliquis growth forecast to 20–25% from 10–15%.

Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

Jul 30, 2026

Bristol Myers Squibb raised its full-year revenue and profit forecast after second-quarter results exceeded Wall Street estimates, driven by strong sales of Eliquis and newer medicines like Camzyos and Reblozyl.

reuters

2026-04-30

Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales

2026-05-15

BMS Is Latest Big Pharma Firm to Partner with China’s Hengrui

2026-05-20

Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

2026-07-30

Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

FAQ